If you’d like to dive deeper, let me know:
Recent consensus updates in Bioresource Technology Vol. 393 and clinical journals discuss the positioning of SGLT2 inhibitors for treating Type 2 Diabetes, emphasizing weight and blood pressure reduction [6, 12]. dass393 updated